SEC Form 4 · accession 0001209191-17-059802
Dova Pharmaceuticals Inc. · DOVA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kevin Laliberte
Officer — Sr. VP, Product Development
Period of report
Nov 6, 2017
Accepted (ET)
Nov 8, 2017 · 5:14 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001685071
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1,F2 | $3.73 | Nov 6, 2017 | A | 24,750 | A | — | Mar 27, 2027 | Common Stock | 24,750 | 24,750 | D |
Explanation of responses
- F1The Reporting Person was granted a stock option on March 28, 2017 (the "Date of Grant") providing for milestone vesting based on the Issuer's successful completion of two Phase IIIB/IV clinical trial protocols as determined and certified in writing by the Board of Directors (the "Board"). Such milestone was achieved on September 29, 2017 and certified by the Board on November 6, 2017. The exercise price of the option is the fair market value of the Issuer's Common Stock on the Date of Grant.
- F2The option shall vest over a period of four years as follows: (i) 25% of the total shares subject to the option shall vest on September 29, 2018, and (ii) the balance of the shares shall vest in a series of thirty-six (36) successive equal monthly installments beginning on October 29, 2018, subject to the Person's continuous service with the Issuer as of each such date. In addition, the option allows for early exercise, subject to the Issuer's repurchase option, with respect to any unvested shares of Common Stock.